Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.

Taiwo B, Hicks C, Eron J.

J Antimicrob Chemother. 2010 Jun;65(6):1100-7. doi: 10.1093/jac/dkq096. Epub 2010 Mar 25. Review.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

The future of antiretroviral therapy: challenges and needs.

Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F; HIV 2020 Project.

J Antimicrob Chemother. 2010 May;65(5):827-35. doi: 10.1093/jac/dkq061. Epub 2010 Mar 12. Review.

4.

HIV-associated neurological disorders: a guide to pharmacotherapy.

Tan IL, McArthur JC.

CNS Drugs. 2012 Feb 1;26(2):123-34. doi: 10.2165/11597770-000000000-00000. Review.

PMID:
22201342
5.

HIV-1 subtypes and response to combination antiretroviral therapy in Europe.

Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A; EuroSIDA Study Group.

Antivir Ther. 2006;11(6):707-15.

PMID:
17310815
6.

HIV-1 drug resistance: can we overcome?

Brenner BG, Turner D, Wainberg MA.

Expert Opin Biol Ther. 2002 Oct;2(7):751-61. Review.

PMID:
12387674
7.

Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Cysique LA, Brew BJ.

Neuropsychol Rev. 2009 Jun;19(2):169-85. doi: 10.1007/s11065-009-9092-3. Epub 2009 May 9. Review.

PMID:
19424802
8.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
9.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

10.

The changing face of HIV/AIDS in treated patients.

Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B.

Curr HIV Res. 2009 Jul;7(4):365-77. Review.

PMID:
19601771
11.

Antiretroviral treatment strategies and immune reconstitution in treatment-naïve HIV-infected patients with advanced disease.

Soria A, Lazzarin A.

J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S19-30. Review.

PMID:
17713422
12.

Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.

Madeddu G, Porqueddu EM, Cambosu F, Saba F, Fois AG, Pirina P, Mura MS.

Infection. 2008 Jun;36(3):231-6. doi: 10.1007/s15010-007-7162-0. Epub 2008 May 10.

PMID:
18463787
13.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
14.

Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.

Bloch M, Farris M, Tilden D, Gowers A, Cunningham N.

Sex Health. 2010 Mar;7(1):17-24. doi: 10.1071/SH09039.

PMID:
20152091
15.

Assessing the efficacy of highly active antiretroviral therapy in the brain.

Kandanearatchi A, Williams B, Everall IP.

Brain Pathol. 2003 Jan;13(1):104-10. Review.

PMID:
12580550
16.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
17.

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.

Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, D'Arrigo R, Trotta MP, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of the HIV Genotype Resistance Test (GRT) at the National Institute for Infectious Diseases "Lazzaro Spallanzani".

Infection. 2009 Jun;37(3):203-9. doi: 10.1007/s15010-008-8142-8. Epub 2009 Mar 9.

PMID:
19274429
18.

[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].

Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F; Kliniek en Virologie van het ATHENA-project.

Ned Tijdschr Geneeskd. 2001 Aug 18;145(33):1591-7. Dutch.

PMID:
11534377
19.

Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease.

Manzardo C, Zaccarelli M, Agüero F, Antinori A, Miró JM.

J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S9-18. Review.

PMID:
17713424
20.

[HIV infection 2007].

Potthoff A, Brockmeyer N; Kompetenznetz HIV/AIDS.

Med Klin (Munich). 2007 Jul 15;102(7):531-9. Review. German.

PMID:
17634871
Items per page

Supplemental Content

Write to the Help Desk